
OssDsign Q2 - Far from fairly priced

Redeye returns with a more detailed take on the Q2 report, and we make some estimate changes that push our base case somewhat down. Still, we emphasise its strong sales development and highlight the unreasonable gap to its peers' EV/sales multiples.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

OssDsign Q2 - Far from fairly priced